BIOLINERX
Careers | Contact Us
search

Drugs in Developement

BL-5010 Skin Lesions
BL-5010

Indication: Benign skin lesions
Mode of action: Mummification and preservation of the lesions
Stage of development: Commercially launched
Patent status: International Patent Application covers the BL-5010P applicator, 20-year expiration in 2033

BL-5010 Overview

BL-5010 is a customized, proprietary pen-like applicator containing a novel, acidic, aqueous solution for the non-surgical removal of skin lesions. In December 2014, BioLineRx entered into an exclusive out-licensing arrangement with a subsidiary of Perrigo Company plc, or Perrigo, for the rights to BL-5010 for over-the-counter, or OTC, indications in the territory of Europe, Australia and additional selected countries. In March 2016, Perrigo received CE Mark approval for BL-5010 as a novel OTC treatment for the non-surgical removal of warts. The commercial launch of this first OTC indication (warts/verrucas) commenced in Europe in the second quarter of 2016 and sales are expected to slowly ramp up over the next 2-3 years.

BL-5010 was invented by Prof. Pinchas Burstein and is being developed by BioLineRx Ltd. under a worldwide exclusive license from Innovative Pharmaceutical Concepts (IPC) Inc.

For more information: bd@BioLineRx.com

Download :

Links :